Suchergebnisse - "Brown, Jennifer R"

PubPharm (447)

31

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Brown, J. | Eichhorst, B. | Hillmen, P. | +25

CommentIn: Nat Rev Clin Oncol. 2023 Feb;20(2):64. - PMID 36543933

32

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

enthalten in: Nature medicine | 2023

von Parry, E. | Leshchiner, I. | Guièze, R. | +51

33

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

enthalten in: bioRxiv : the preprint server for biology | 2023

von Arribas, A. | Napoli, S. | Cascione, L. | +21

UpdateIn: Mol Cancer Ther. 2023 Dec 05;:OF1-OF13. - PMID 38052765

34

PI3K inhibitors in chronic lymphocytic leukemia : where do we go from here?

enthalten in: Haematologica | 2023

von Skånland, S. | Brown, J.

35

Selecting initial therapy in CLL

enthalten in: Hematology. American Society of Hematology. Education Program | 2022

von Ahn, I. | Brown, J.

36

Molecular map of chronic lymphocytic leukemia and its impact on outcome

enthalten in: Nature genetics | 2022

von Knisbacher, B. | Lin, Z. | Hahn, C. | +36

37

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

enthalten in: Haematologica | 2022

von Arribas, A. | Napoli, S. | Cascione, L. | +22

38

Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Yin, Y. | Athanasiadis, P. | Karlsen, L. | +14

39

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) : a randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Tam, C. | Brown, J. | Kahl, B. | +28

CommentIn: Lancet Oncol. 2022 Aug;23(8):965-967. - PMID 35810752

40

PI3K inhibitors in haematological malignancies

enthalten in: The Lancet. Oncology | 2022

von Brown, J. | Danilov, A. | LaCasce, A. | +1

CommentOn: Lancet Oncol. 2022 May;23(5):563-566. - PMID 35429996